In experimental studies, ALYREF knockdown significantly inhibited HCC cell proliferation and tumor growth, suggesting that ALYREF may be a potential prognostic marker and therapeutic target (Xue et al., 2023; Nulali et al., 2024). Here, ALYREF is linked to hepatocellular carcinoma.